NanoString Technologies, Inc.
NanoString Technologies, Inc.
Your view on NSTG
Overview
What the company does, where it operates, and who runs it.
About NanoString Technologies, Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- R. Bradley Gray
- Headquarters
- US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- R. Bradley Gray
- Headquarters
- US
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system.
It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.
The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data.
In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits.
The company is also developing GeoMx DSP system to enable the field of spatial genomics.
It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer.
NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for NanoString Technologies, Inc. from FRC's valuation model, read against the market price. NSTG last traded at $0.11; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for NanoString Technologies, Inc.. Starting points for NanoString Technologies, Inc.: EPS -$3.44, beta 1.24 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for NanoString Technologies, Inc.. NanoString Technologies, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for NanoString Technologies, Inc.. Trailing twelve-month EPS for NanoString Technologies, Inc. stands at -$3.44. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$21.50
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy7
- Hold6
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2023 | Next QtrMar 2024 | Current YearFY Dec 2023 | Next YearFY Dec 2024 |
|---|---|---|---|---|
| Avg. estimate | -$0.63 | -$0.53 | -$3.22 | -$1.69 |
| Low estimate | -$0.70 | -$0.53 | -$3.26 | -$1.77 |
| High estimate | -$0.56 | -$0.53 | -$3.16 | -$1.62 |
| No. of analysts | 2 | 1 | 3 | 3 |
| Year-ago EPS | -$0.951 | -$0.88 | -$3.441 | — |
| Growth | — | +39.4% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2023 | Next QtrMar 2024 | Current YearFY Dec 2023 | Next YearFY Dec 2024 |
|---|---|---|---|---|
| Avg. estimate | $48.52M | $44.81M | $176.75M | $201.13M |
| Low estimate | $46.93M | $44.02M | $175.20M | $195.77M |
| High estimate | $49.42M | $45.60M | $177.62M | $207.54M |
| No. of analysts | 2 | 1 | 3 | 3 |
| Year-ago revenue | $34.42M | $35.80M | $127.26M | — |
| Growth | +41.0% | +25.2% | +38.9% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from Benzinga; as of Nov 15, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for NanoString Technologies, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- NEUPNeuphoria Therapeutics Inc.Biotechnology$14M
- RHEPRegional Health Properties, Inc.Medical - Care Facilities$3M
More Medical - Instruments & Supplies companies
- SHWGYShandong Weigao Group Medical Polymer Company LimitedOTC$3.0B
- SMTISanara MedTech Inc.NASDAQ$297M
- SOAGYSartorius AGOTC$82.3B
- SOLVSolventum CorporationNYSE$15.1B
- SRTOYSartorius Stedim Biotech S.A.OTC$209.8B
- SSSGYSartorius AGOTC$15.8B
- STAASTAAR Surgical CompanyNASDAQ$1.3B
- STSSSharps Technology, Inc.NASDAQ$54M
- STVNStevanato Group S.p.A.NYSE$4.3B
- STXSStereotaxis, Inc.AMEX$84M
- SUVPFSartorius AGOTC$18.7B
- SVSOSheerVision, Inc.OTC$2,551
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by NanoString Technologies, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for NanoString Technologies, Inc.. Coverage tracks NanoString Technologies, Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of NanoString Technologies, Inc.